Last checked at 24 Dec 2020 12:56
Tissue Regenix Group plc
Issue of Equity and Total Voting Rights - Replacement
Correction to announcement released at 09.51 on 23 December 2020 under RNS reference 6693J. The original announcement incorrectly stated that the nominal value of shares issued and allotted was 0.5p when it should have stated 0.1p. The corrected announcement is set out below. No other information has been updated.
Leeds, 23 December 2020 - Tissue Regenix Group plc (AIM:TRX) ("the Company"), the regenerative medical devices company, announces that it has issued and allotted 91,743 ordinary shares of 0.1p each in the Company, following an exercise of options which were granted in respect of the 2018 DAB option scheme.
The 91,743 new ordinary shares will rank pari passu with the existing ordinary shares and application will shortly be made for these new ordinary shares to be admitted to trading on AIM. It is expected that Admission will occur at 8:00a.m. on 31 December 2020.
Total Voting Rights
Following the issue of the 91,743 new ordinary shares, the Company will have a total of 7,033,077,499 ordinary shares of 0.1p each in issue. The above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
For more Information:
Tissue Regenix Group plc Caitlin Pearson Head of Communications |
Tel: 0330 430 3052 |
|
|
Stifel Nicolaus Europe Limited (Nominated Adviser and Broker) Ben Maddison / Alex Price | Tel: 0207 710 7600
|
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.
In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopaedic, foot & ankle, dental, and sports medicine surgical procedures.